Published on September 22, 2014

In the intricate field of drug manufacturer and technology the Indian pharmaceutical industry is currently noted on the top of the chart amid the science based industries of India through wide ranging capabilities. According to the researched report, the Indian pharmaceutical industry which is noted as a highly organized sector growing at around 8 to 9% and has been estimated at the cost of USD 4.5 billion. In the year 2013, the Indian pharmaceutical industry is expected to boost around 19%, whereas around 13-14% rise is expected to register a sturdy double digit in the domestic pharmaceutical.

According to the researched report, in the US expiry of drug patents is great news for consumers as well as for the domestic pharmaceutical industry, where generics report for around 75% of total sales. Moreover patented drugs worth around USD 92 billion are expected to go off-patent in the US during the year 2014-2016, in comparison to USD 65 billion in the year 2010-12. However in local demand and the US the pharma industry might see a growth on back of patent expiry of few blockbuster drugs.

Amid the other pharma industries, huge number of drugs going off-patent in the US offers opportunities for local generic drug makers which includes major pharma industries such as Cipla, Sun Pharmaceutical, Lupin and Dr Reddy’s laboratories. Moreover on the back of increasing material comfort, rising government expenditure on healthcare, etc. the sale of the domestic market will also see a noteworthy growth in the near future.